HYPERRAB 300 UNIT — DIN 02486571
RABIES IMMUNOGLOBULIN (HUMAN) : 300 UNIT · GRIFOLS THERAPEUTICS LLC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is HYPERRAB?
HYPERRAB 300 UNIT contains RABIES IMMUNOGLOBULIN (HUMAN) : 300 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02486571, held by GRIFOLS THERAPEUTICS LLC, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 02-Jul-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HYPERRAB used for?
HyperRAB® (Rabies Immunoglobulin [Human]) is indicated for post-exposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies. HyperRAB® should be administered as promptly as possible after exposure, but can be administered up to and including 7 days after Day 0 (the day the first dose of vaccine is administered).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Rabies Immunoglobulin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Rabies Immunoglobulin, across 7 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GRIFOLS THERAPEUTICS LLC | 2 | 1 | HYPERRAB, HYPERRAB S/D | Sourceable in Canada |
| KAMADA LTD | 2 | 1 | KAMRAB | Sourceable in Canada |
| CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | 1 | 0 | HYPERAB RABIES IMMUNE GLOBULIN HUMAN | No marketed DIN |
| PASTEUR MÉRIEUX SERUMS ET VACCINS, S.A. | 1 | 0 | IMOGAM RABIES INJ 150UNIT/ML | No marketed DIN |
| SANOFI PASTEUR LIMITED | 1 | 0 | IMOGAM RABIES PASTEURIZED | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 UNIT |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | 1 mL, 3 mL and 5 mL single use vials (300 IU, 900 IU, 1500 IU respectively) |
| Storage | Should be stored at 2 – 8°C. Do not freeze. During the shelf-life, HyperRAB® may also be stored at room temperature (not more than 25ºC) for a period of up to 6 months. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Rabies Immunoglobulin |
|---|---|
| ATC code | J06BB05 |
| AHFS class | 80:04.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02486571 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2486571 |
| Brand name | HYPERRAB |
| Generic / active ingredient | RABIES IMMUNOGLOBULIN (HUMAN) : 300 UNIT |
| Market authorization holder | GRIFOLS THERAPEUTICS LLC |
| Health Canada schedule | Schedule D |
| ATC code | J06BB05 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J06BB |
| Current status | MARKETED |
| Status date | 02-Jul-2019 |
| Original market date | 2019-07-02 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 7 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| KAMRAB | 150 UNIT | SOLUTION | KAMADA LTD | MARKETED | 02482436 |
| HYPERAB RABIES IMMUNE GLOBULIN HUMAN | 16.5 % | LIQUID | CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | CANCELLED POST MARKET | 00345733 |
| HYPERRAB S/D | 150 UNIT | SOLUTION | GRIFOLS THERAPEUTICS LLC | CANCELLED POST MARKET | 02230700 |
| IMOGAM RABIES INJ 150UNIT/ML | 150 UNIT | LIQUID | PASTEUR MÉRIEUX SERUMS ET VACCINS, S.A. | CANCELLED POST MARKET | 01910477 |
| IMOGAM RABIES PASTEURIZED | 150 UNIT | SOLUTION | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | 02237328 |
| KAMRAB | 150 UNIT | SOLUTION | KAMADA LTD | APPROVED | 02482509 |
2 · Same class — other molecules in ATC J06BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Hepatitis B Immunoglobulin | H-BIG · HEPAGAM B · HYPERHEP B · HYPERHEP B S/D · +1 more | 9 | 3 | Yes |
| Anti-D (Rh) Immunoglobulin | HYP RHO D INJ 16.5% · WINRHO SD KIT INJ · WINRHO SD KIT INJ. · WINRHO SDF | 11 | 2 | Yes |
| Rabies Immunoglobulin | HYPERAB RABIES IMMUNE GLOBULIN HUMAN · HYPERRAB · HYPERRAB S/D · IMOGAM RABIES INJ 150UNIT/ML · +2 more | 7 | 2 | Yes |
| Tetanus Immunoglobulin | HYPER TET · HYPERTET · HYPERTET S/D | 4 | 1 | Yes |
| Varicella/Zoster Immunoglobulin | VARICELLA ZOSTER IMMUNE GLOBULIN INJ · VARICELLA-ZOSTER IMMUNE GLOBULIN (HUMAN) · VARIZIG | 4 | 1 | Yes |
| Cytomegalovirus Immunoglobulin | CYTOGAM | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J06B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J06BA | Immunoglobulins, Normal Human, For Extravasc. Adm · Immunoglobulins, Normal Human, For Intravasc. Adm. | 50 | 16 |
| J06BD | Casirivimab And Imdevimab · Nirsevimab · Palivizumab · Sipavibart · Sotrovimab · +1 more | 11 | 2 |
| J06B | Immunoglobulins | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is HYPERRAB called?
The same molecule, Rabies Immunoglobulin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Verorab | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.